Orlova D A, Kudriaeva A A, Kolotyeva N A, Ivanova E O, Fedotova E Yu, Tregub P P, Salmina A B, Illarioshkin S N, Jr A A Belogurov
Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.
Brain Science Institute, Research Center of Neurology, Moscow, 125367 Russia.
Acta Naturae. 2025 Apr-Jun;17(2):110-117. doi: 10.32607/actanaturae.27530.
Neurodegenerative disorders classified as synucleinopathies (Parkinson's disease, dementia with Lewy bodies, and multiple-system atrophy) are characterized by the accumulation of aberrant α-synuclein aggregates in neurons and glial cells. These diseases manifest clinically several years after the initial formation of pathological protein aggregates in the brain, making early and accurate diagnosis challenging. In recent years, a new method, which is based on real-time quaking-induced conversion (RT-QuIC) of α-synuclein, has been developed and validated. This technology holds great promise as a powerful diagnostic tool for the early and precise identification of synucleinopathies, potentially opening new horizons in the study of neurodegenerative diseases. RT-QuIC detects misfolded α-synuclein aggregates in human physiological fluids by introducing an excess of recombinant α-synuclein, which undergoes conformational conversion in an exponential, prion-like manner. The production of high-quality recombinant α-synuclein is a critical step in the effective application of this method, as protein purity significantly affects the sensitivity and specificity of the assay - key factors in its diagnostic utility. Using a three-step chromatographic purification protocol, we produced recombinant monomeric α-synuclein with a purity exceeding 97% from the periplasmic fraction of bacterial cells. While higher purity increases the assay duration, it also reduces the background signal and permits extended incubation times, which are essential for reliably detecting synucleinopathies with weak RT-QuIC responses, such as the cerebellar subtype of multiple-system atrophy. The data presented support the conclusion that optimized components of the RT-QuIC system will enable an accurate diagnosis of neurodegenerative synucleinopathies.
被归类为突触核蛋白病(帕金森病、路易体痴呆和多系统萎缩)的神经退行性疾病,其特征是异常的α-突触核蛋白聚集体在神经元和神经胶质细胞中积累。这些疾病在大脑中病理性蛋白质聚集体最初形成数年之后才会出现临床症状,这使得早期准确诊断具有挑战性。近年来,一种基于α-突触核蛋白实时震颤诱导转化(RT-QuIC)的新方法已被开发并验证。这项技术作为一种强大的诊断工具,有望用于早期精确识别突触核蛋白病,可能为神经退行性疾病的研究开辟新的视野。RT-QuIC通过引入过量的重组α-突触核蛋白来检测人体生理体液中错误折叠的α-突触核蛋白聚集体,该重组α-突触核蛋白会以指数级、朊病毒样的方式发生构象转化。高质量重组α-突触核蛋白的生产是该方法有效应用的关键步骤,因为蛋白质纯度会显著影响检测的灵敏度和特异性,而这两个因素是其诊断效用的关键。我们使用三步色谱纯化方案,从细菌细胞的周质部分生产出了纯度超过97%的重组单体α-突触核蛋白。虽然更高的纯度会延长检测时间,但它也会降低背景信号并允许延长孵育时间,这对于可靠检测RT-QuIC反应较弱的突触核蛋白病(如多系统萎缩的小脑亚型)至关重要。所呈现的数据支持这样的结论:RT-QuIC系统的优化组件将能够准确诊断神经退行性突触核蛋白病。